• 1
    Cheung RT. Cerebrovascular disease – advances in management. Hong Kong Med J 2001; 7: 5866.
  • 2
    Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol 1996; 6: 667672.
  • 3
    Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999; 399 (suppl): A7A14.
  • 4
    Buchan, A. Advances in cerebral ischemia: experimental approaches. Neurol Clin 1992; 10: 4961.
  • 5
    O'neill M, Allain H, Bentue-Ferrer D et al. Pharmacological strategies in the treatment of cerebral ischemia. Eur Neurol 1995; 35 (suppl 1):2836.
  • 6
    Pulsinelli WA. Selective neuronal vulnerability: morphological and molecular characteristics. Prog Brain Res 1985; 63: 2937.
  • 7
    Dirnagl U. Cerebral ischemia: the microcirculation as trigger and target. Prog Brain Res 1993; 96: 4965.
  • 8
    Lucchesi BR. Complement activation, neutrophils, and oxygen radicals in reperfusion injury. Stroke 1993; 24 (suppl I): I41I47.
  • 9
    The National Institute of Neurological Disordersand Stroke RT-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Eng J Med 1995; 333: 15811587.
  • 10
    Furlan A, Higashida R, Wechsler L et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 20032011.
  • 11
    Sherman DG, Atkinson RP, Chippendale T et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000; 283: 23952403.
  • 12
    Martinez-Vila E, Irimia-Sieira P. Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 2001; 11 (suppl 1): 6070.
  • 13
    Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994; 36: 557565.
  • 14
    Hossmann KA. Disturbances of cerebral protein synthesis and ischemic cell death. Prog Brain Res 1993; 96: 161177.
  • 15
    Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia. Part I: pathophysiology. J Neurosurg 1992; 77: 169184.
  • 16
    Alonso de Lecinana M, Diez-Tejedor E, Carceller F et al. Cerebral ischemia: from animal studies to clinical practice. Should the methods be reviewed? Cerebrovasc Dis 2001; 11 (suppl 1): 2030.
  • 17
    Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 1982; 11: 491498.
  • 18
    Pulsinelli WA, Levy DE, Duffy TE. Regional cerebral blood flow and glucose metabolism following transient forebrain ischemia. Ann Neurol 1982; 11: 499509.
  • 19
    Paschen W. Role of calcium in neuronal cell injury: which subcellular compartment is involved? Brain Res Bull 2000; 53: 409413.
  • 20
    Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001; 21: 214.
  • 21
    Iadecola C, Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001; 14: 8994.
  • 22
    Petty MA, Wettstein JG. Elements of cerebral microvascular ischaemia. Brain Res Rev 2001; 36: 2334.
  • 23
    Emerich DF, Dean RL III, Bartus RT. The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? Exp Neurol 2002; 173: 168181.
  • 24
    Leker RR, Shohami E. Cerebral ischemia and trauma – different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res Rev 2002; 39: 5573.
  • 25
    Ikonomidou C, Turski L. Excitotoxicity and neurodegenerative diseases. Curr Opin Neurol 1995; 8: 487497.
  • 26
    Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994; 78: 927930.
  • 27
    Forstermann U, Closs EI, Pollock JS et al. Nitric Oxide Synthase isoenzymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 11211131.
  • 28
    Forstermann U, Boissel JP, Kleinert H. Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12: 773790.
  • 29
    Moncada S, Palmer RM, Higgs EA. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989; 38: 17091715.
  • 30
    Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 1991; 14: 6067.
  • 31
    Christopherson KS, Bredt DS. Nitric oxide in excitable tissues: physiological roles and disease. J Clin Invest 1997; 100: 24242429.
  • 32
    Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke 1997; 28: 12831288.
  • 33
    Reiter RJ, Tan DX, Manchester LC et al. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 2001; 34: 237256.
  • 34
    Sastry PS, RAO KS. Apoptosis and the nervous system. J Neurochem 1997; 74: 120.
  • 35
    Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56: 359384.
  • 36
    Reiter RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 1995; 9: 526533.
  • 37
    Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflammation Res 1995; 44: 110.
  • 38
    Cheung RT, Pei Z, Feng ZH et al. Cyclooxygenase-1-gene knockout does not alter middle cerebral artery occlusion in a mouse stroke model. Neurosci Lett 2002; 330: 5760.
  • 39
    Cuzzocrea S, Reiter RJ. Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury. Eur J Pharmacol 2001; 426: 110.
  • 40
    Snider BJ, Gottron FJ, Choi DW. Apoptosis and necrosis in cerebrovascular disease. Ann N Y Acad Sci 1999; 893: 243253.
  • 41
    Giusti P, Gusella M, Lipartiti M et al. Melatonin protects primary cultures of cerebellar granule neurons from kainate but not from N-methyl-D-aspartate excitotoxicity. Exp Neurol 1995; 131: 3946.
  • 42
    Lezoualc'h F, Sparapani M, Widmann M et al. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res 1998; 24: 168178.
  • 43
    Lezoualc'h F, Skutella T, Widmann M et al. Melatonin prevents oxidative stress-induced cell death in hippocampal cells. Neuroreport 1996; 7: 20712077.
  • 44
    Giusti P, Lipartiti M, Franceschini D et al. Neuroprotection by melatonin from kainate-induced excitotoxicity in rats. FASEB J 1996; 10: 891896.
  • 45
    Uz T, Giusti P, Franceschini D et al. Protective effect of melatonin against hippocampal DNA damage induced by intraperitoneal administration of kainate to rats. Neuroscience 1996; 73: 631636.
  • 46
    Giusti P, Franceschini D, Petrone M et al. In vitro and in vivo protection against kainate-induced excitotoxicity by melatonin. J Pineal Res 1996; 20: 226231.
  • 47
    Manev H, Uz T, Kharlamov A et al. In vivo protection against kainate-induced apoptosis by the pineal hormone melatonin: effect of exogenous melatonin and circadian rhythm. Restor Neurol Neurosci 1996; 9: 251256.
  • 48
    Manev H, Uz T, Kharlamov A et al. Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J 1996; 10: 15461551.
  • 49
    Tan DX, Manchester LC, Reiter RJ et al. Melatonin protects hippocampal neurons in vivo against kainic acid-induced damage in mice. J Neurosci Res 1998; 54: 382389.
  • 50
    Behan WM, Mcdonald M, Darlington LG et al. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 1999; 128: 17541760.
  • 51
    Husson I, Mesples B, Bac P et al. Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann Neurol 2002; 51: 8292.
  • 52
    Bertuglia S, Marchiafava PL, Colantuoni A. Melatonin prevents ischemia reperfusion injury in hamster cheek pouch microcirculation. Cardiovasc Res 1996; 31: 947952.
  • 53
    Joo JY, Uz T, Manev H. Opposite effects of pinealectomy and melatonin administration on brain damage following cerebral focal ischemia in rat. Restor Neurol Neurosci 1998; 13: 18591.
  • 54
    Kilic E, Ozdemir YG, Bolay H et al. Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J Cereb Blood Flow Metab 1999; 19: 511516.
  • 55
    Borlongan CV, Yamamoto M, Takei N et al. Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J 2000; 14: 13071317.
  • 56
    Sinha K, Degaonkar MN, Jagannathan NR et al. Effect of melatonin on ischemia reperfusion injury induced by middle cerebral artery occlusion in rats. Eur J Pharmacol 2001; 428: 185192.
  • 57
    Pei Z, Ho HT, Cheung RT. Pretreatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci Lett 2002; 318: 141144.
  • 58
    Pei Z, Pang SF, Cheung RT. Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J Pineal Res 2002; 32: 168172.
  • 59
    Pei Z, Pang SF, Cheung RT. Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke 2003; 34: 770775.
  • 60
    Pei Z, Fung PC, Cheung RT. Melatonin reduces nitric oxide level during ischemia but not blood-brain-barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. J Pineal Res 2003; 34: 110118.
  • 61
    Gupta YK, Chaudhary G, Sinha K. Enhanced protection by melatonin and meloxicam combination in a middle cerebral artery occlusion model of acute ischemic stroke in rat. Can J Physiol Pharmacol 2002; 80: 210217.
  • 62
    Cho S, Joh TH, Baik HH et al. Melatonin administration protects CA1 hippocampal neurons after transient forebrain ischemia in rats. Brain Res 1997; 755: 335338.
  • 63
    Guerrero JM, Reiter RJ, Ortiz GG et al. Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meriones Unguiculatus). J Pineal Res 1997; 23: 2431.
  • 64
    Cuzzocrea S, Costantino G, Gitto E et al. Protective effects of melatonin in ischemic brain injury. J Pineal Res 2000; 29: 217227.
  • 65
    Wakatsuki A, Okatani Y, Izumiya C et al. Melatonin protects against ischemia and reperfusion-induced oxidative lipid and DNA damage in fetal rat brain. J Pineal Res 1999; 26: 147152.
  • 66
    Letechipia-Vallejo G, Gonzalez-Burgos I, Cervantes M. Neuroprotective effect of melatonin on brain damage induced by acute global cerebral ischemia in cats. Arch Med Res 2001; 32: 186192.
  • 67
    de Butte M, Fortin T, Pappas BA. Pinealectomy: behavioral and neuropathological consequences in chronic cerebral hypoperfusion model. Neurobiol Aging 2002; 23: 309317.
  • 68
    Shaikh AY, Xu J, Wu Y et al. Melatonin protects bovine cerebral endothelial cells from hyperoxia-induced DNA damage and death. Neurosci Lett 1997; 229: 193197.
  • 69
    Cazevieille C, Safa R, Osborne NN. Melatonin protects primary cultures of rat cortical neurons from NMDA excitotoxicity and hypoxia/reoxygenation. Brain Res 1997; 768: 120124.
  • 70
    Yamamoto HA, Tang HW. Effects of 2-amino-7-phosphonoheptanoic acid, melatonin or NG-nitro-L-arginine on cyanide or N-methyl-D-aspartate-induced neurotoxicity in rat cortical cells. Toxicol Lett 1998; 94:1318.
  • 71
    Skaper SD, Ancona B, Facci L et al. Melatonin prevents the delayed death of hippocampal neurons induced by enhanced excitatory neurotransmission and the nitridergic pathway. FASEB J 1998; 12: 725731.
  • 72
    Olivieri G, Hess C, Savaskan E et al. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased β-amyloid secretion. J Pineal Res 2001; 31: 320325.
  • 73
    Clapp-Lilly KL, Smith MA, Perry G et al. Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity. Int J Circumpolar Health 2002; 61: 3240.
  • 74
    Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999; 79: 14311568.
  • 75
    Harms C, Lautenschlager M, Bergk A et al. Melatonin is protective in necrotic but not in caspase-dependent, free radical-independent apoptotic neuronal cell death in primary neuronal cultures. FASEB J 2000; 14: 18141824.
  • 76
    Pei Z, Cheung RT. Melatonin protects SHSY5Y neuronal cells but not cultured astrocytes from ischemia due to oxygen and glucose deprivation. J Pineal Res 2003; 34: 194201.
  • 77
    Voordouw BC, Euser R, Verdonk RE et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992; 74: 108117.
  • 78
    Tan DX, Chen LD, Poeggeler B et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J 1993; 1: 5760.
  • 79
    Reiter R, Tang L, Garcia JJ et al. Pharmacological actions on melatonin in oxygen radical pathophysiology. Life Sci 1997; 60: 22552271.
  • 80
    Acuna-Castroviejo D, Martin M, Macias M et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001; 30: 6574.
  • 81
    Crespo E, Macias M, Pozo D et al. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 1999; 13: 15371546.
  • 82
    Gilad E, Wong HR, Zingarelli B et al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFκB activation. FASEB J 1998; 12: 685693.
  • 83
    Reiter RJ, Tan DX. Role of CSF in the transport of melatonin. J Pineal Res 2002; 32: 279.